Oxulumis® – microcatheterization

Hands-on session: info & booking

About Oxulumis®

Oxulumis® is a semi-automated ocular administration device for minimally invasive delivery of retinal therapeutics, via deployment of a specially designed microcatheter into the posterior region of the suprachoroidal space. A 27-gauge needle, which accommodates variation in scleral thickness across most patients, is inserted in the pars plana of the eye. As the needle advances, the microcatheter deploys automatically once the tip of the needle reaches the suprachoroidal space, advancing posteriorly toward the macular, where the drug product will be delivered.

The Oxulumis® microcatheter is lubricious and flexible to promote advancement and employs an atraumatic (soft) tip to promote safety. The microcatheter is illuminated which allows trans-scleral visualization by direct observation, providing absolute confirmation of accurate placement of the microcatheter in the suprachoroidal space prior to administration of the drug product.

The drug product is deposited into the posterior suprachoroidal space and the natural physiological flows of the suprachoroidal space allow the drug product to migrate even more posteriorly.

The Oxulumis® device was extensively tested in animal models and is being successfully used in compassionate human cases.

Microcatheterization in In Vivo Porcine Model

Catheter in suprachoroidal space
Withdrawn from eye

Key features of the Oxulumis suprachoroidal space microcatheter

  • Novel, semi-automated ocular administration device
  • Utilizes the suprachoroidal space, which is an advantageous route of administration to specific tissues involved in retinal disease
  • Pars plana site administration
  • Delivers therapeutics via an illuminated microcatheter to posterior segment of the suprachoroidal space
  • Visual confirmation of microcatheter placement in suprachoroidal space to ensures accurate drug delivery

Key benefits of the Oxulumis suprachoroidal space microcatheterization

  • Minimally invasive procedure does not penetrate the intraocular space
  • Safely delivers long-lasting drug products alongside the posterior retina and macula
  • Offers ophthalmologists a novel, site-specific administration procedure

Oxulumis human case study

Hands-on Oxulumis microcatheterization procedure

Your Oxulumis microcatheterization session includes: 

Case study review: Prof. Marc D de Smet, shares his human use Oxulumis experience, presenting a microcatheterization human case study and patient response. 

Try out the device: use the device yourself in Oxular’s proprietary model eye, to get a more visceral understanding of the suprachoroidal microcatheterization procedure and the advantages of the Oxulumis device.

Technical exchange: Oxular senior management team will be on hand to discuss your thoughts and answer questions about the Oxulumis device and microcatheterization procedure.


7-12 October (adjecent to ASRS conference; times vary. See calendar below for all options.)


JW Marriott San Antonio Hill Country Resort & Spa

Length of session

c.30 mins


Tom Cavanagh (CEO)
Fritz Asmus (CMO)

Book a convenient time to meet us

About Oxular

“One treatment a year. Life changing.”

Oxular is developing disruptive technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally-invasive delivery. This novel combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and age-related macular degeneration, as well as rare and orphan indications, including treatments for ocular cancers.

Oxular Logo
Scroll to Top